ESMO 2022 | Updated analysis from MOUNTAINEER: tucatinib and trastuzumab for HER2-positive mCRC

John Strickler, MD, Duke Cancer Center, Durham, NC, presents additional analyses of MOUNTAINEER (NCT03043313), a Phase II study of tucatinib and trastuzumab for HER2-positive metastatic colorectal cancer (mCRC). Tucatinib monotherapy and tucatinib with trastuzumab after crossover were well tolerated, consistent with the primary analysis, with 18% of patients who crossed over achieving a response. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.